Biodegradable microspherical implants containing teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
BACKGROUND
The aim of this study was to prepare poly(d,l-lactide-co-glycolide) (PLGA) microspherical implants containing teicoplanin (TCP) using a double emulsion solvent evaporation method and to evaluate its efficacy for the local treatment of chronic osteomyelitis.


METHODS
The particle size and distribution, morphological characteristics, thermal behaviour, drug content, encapsulation efficiency and in vitro release assessments of the formulations were carried out. Sterile TCP–PLGA microspheres were implanted in the proximal tibia of rats with methicillin resistant Staphylococcus aureus (MRSA) osteomyelitis. After 3 weeks of treatment, bone samples were analysed with a microbiological assay and evaluated histopathologically.


RESULTS
Microspheres between the size ranges of 2.01 and 3.91 μm were obtained. Production yield of all formulations was found to be higher than 82% and encapsulation efficiencies of 33.6–69.8% were obtained. DSC thermogram showed that the TCP was in an amorphous state in microspheres. In vitro drug release studies had indicated that the drug release rate of microspheres was decreased upon increasing the polymer:drug ratio. Based on the in vivo data, rats treated with implants and intramuscular injection showed 1.7 × 10(3) ± 1.3 × 10(3) and 5.8 × 10(4) ± 5.3 × 10(4) colony forming unit of MRSA in 1 g bone samples (CFU/g), respectively (P < 0.01).


CONCLUSIONS
The in vitro and in vivo studies had shown that the TCP–PLGA microspheres were effective for the treatment of chronic osteomyelitis in an animal experimental model. Hence, these microspheres may be potentially useful in the clinical setting with the need for further investigation for optimal dosing of TCP–PLGA microspheres.
Department of Orthopaedics, School of Medicine, Düzce University, 81620 Düzce, Turkey. zorhan@excite.com
Zafer
Z
Orhan
Erdal
E
Cevher
Ayca
A
Yildiz
Rengin
R
Ahiskali
Demet
D
Sensoy
Lütfiye
L
Mülazimoğlu
D020341:Absorbable Implants; D000704:Analysis of Variance; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D019344:Lactic Acid; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus; D008863:Microspheres; D010019:Osteomyelitis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010316:Particle Size; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011859:Radiography; D051381:Rats; D017208:Rats, Wistar; D013203:Staphylococcal Infections / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013977:Tibia
D000900:Anti-Bacterial Agents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid